Tachycardia or tachyarrhythmia is used to describe the presence of cardiac rhythm abnormality in states when cardiac rate is increased to >100 bpm.
Divided into supraventricular and ventricular tachycardia.
Signs and symptoms related to rapid heart rate are altered sensorium,
angina, shortness of breath, myocardial infarction, hypotension and
other signs of shock (eg cold clammy skin, low urine output), heart
failure or pulmonary congestion.
Targeting a low-density lipoprotein cholesterol level <70 mg/dL following an ischaemic stroke of atherosclerotic origin helps to avoid one in four subsequent major vascular events without increasing the risk of intracranial haemorrhage over about 5 years of follow-up, according to data from the Treat Stroke to Target trial.
Early initiation of rhythm-control therapy led to a significantly reduced risk of major adverse cardiovascular (CV) outcomes compared with usual care (typically rate control) in patients with newly diagnosed atrial fibrillation (AF) at risk of stroke, reveals the EAST-AFNET 4* trial presented at ESC 2020.